Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer

NCT00064259 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00064259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00064259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Oblimersen in Combination With Cisplatin and Fluorouracil in Patients With Advanced Esophageal, Gastro-Esophageal Junction and Gastric Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2003
Completion date
February 28, 2010
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the esophagus, adenocarcinoma of the gastroesophageal junction, diffuse adenocarcinoma of the stomach, intestinal adenocarcinoma of the stomach, mixed adenocarcinoma of the stomach, recurrent esophageal cancer, recurrent gastric cancer, squamous cell carcinoma of the esophagus, stage iii esophageal cancer, stage iiia gastric cancer, stage iiib gastric cancer, stage iiic gastric cancer, stage iv esophageal cancer, stage iv gastric cancer